Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism

The R,R enantiomer of 5,11-cis-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol (THC) exerts opposite effects on the transcriptional activity of the two estrogen receptor (ER) subtypes, ERα and ERβ. THC acts as an ERα agonist and as an ERβ antagonist. We have determined the crystal structures of the ERα ligand binding domain (LBD) bound to both THC and a fragment of the transcriptional coactivator GRIP1, and the ERβ LBD bound to THC. THC stabilizes a conformation of the ERα LBD that permits coactivator association and a conformation of the ERβ LBD that prevents coactivator association. A comparison of the two structures, taken together with functional data, reveals that THC does not act on ERβ through the same mechanisms used by other known ER antagonists. Instead, THC antagonizes ERβ through a novel mechanism we term 'passive antagonism'.

[1]  B. Katzenellenbogen,et al.  Ligand-dependent, transcriptionally productive association of the amino- and carboxyl-terminal regions of a steroid hormone nuclear receptor. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[2]  R M Esnouf,et al.  An extensively modified version of MolScript that includes greatly enhanced coloring capabilities. , 1997, Journal of molecular graphics & modelling.

[3]  P. Chambon,et al.  Role of the two activating domains of the oestrogen receptor in the cell‐type and promoter‐context dependent agonistic activity of the anti‐oestrogen 4‐hydroxytamoxifen. , 1990, The EMBO journal.

[4]  A. Steinmetz,et al.  Binding of ligands and activation of transcription by nuclear receptors. , 2001, Annual review of biophysics and biomolecular structure.

[5]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[6]  M Carlquist,et al.  Structure of the ligand‐binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist , 1999, The EMBO journal.

[7]  E J Dodson,et al.  Collaborative Computational Project, number 4: providing programs for protein crystallography. , 1997, Methods in enzymology.

[8]  B. Katzenellenbogen,et al.  Estrogen receptor transcription and transactivation Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer , 2000, Breast cancer research : BCR.

[9]  G J Kleywegt,et al.  Software for handling macromolecular envelopes. , 1999, Acta crystallographica. Section D, Biological crystallography.

[10]  J. Gustafsson,et al.  Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. , 1998, Molecular pharmacology.

[11]  B. Katzenellenbogen,et al.  Transcription Activation by the Human Estrogen Receptor Subtypeβ (ERβ) Studied with ERβ and ERα Receptor Chimeras* *This work was supported by NIH Grants CA-18119 and CA-60514 (to B.S.K.). , 1998, Endocrinology.

[12]  W Furey,et al.  PHASES-95: a program package for processing and analyzing diffraction data from macromolecules. , 1997, Methods in enzymology.

[13]  F. Labrie,et al.  Androgen receptor antagonists (antiandrogens): structure-activity relationships. , 2000, Current medicinal chemistry.

[14]  K E Carlson,et al.  Estrogen receptor subtype-selective ligands: asymmetric synthesis and biological evaluation of cis- and trans-5,11-dialkyl- 5,6,11, 12-tetrahydrochrysenes. , 1999, Journal of medicinal chemistry.

[15]  M Carlquist,et al.  Structural insights into the mode of action of a pure antiestrogen. , 2001, Structure.

[16]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[17]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[18]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[19]  S. Harrison,et al.  The structure of simian virus 40 refined at 3.1 A resolution. , 1996, Structure.

[20]  G. Kleywegt,et al.  Detecting folding motifs and similarities in protein structures. , 1997, Methods in enzymology.

[21]  C. Glass,et al.  The coregulator exchange in transcriptional functions of nuclear receptors. , 2000, Genes & development.

[22]  J. Lees,et al.  Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. , 1992, The EMBO journal.

[23]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[24]  E A Merritt,et al.  Raster3D: photorealistic molecular graphics. , 1997, Methods in enzymology.

[25]  B. Katzenellenbogen,et al.  Conformational Changes and Coactivator Recruitment by Novel Ligands for Estrogen Receptor-α and Estrogen Receptor-β: Correlations with Biological Character and Distinct Differences among SRC Coactivator Family Members. , 2000, Endocrinology.

[26]  P. Chambon,et al.  Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. , 2000, Molecular cell.

[27]  J. Fagart,et al.  The mineralocorticoid activity of progesterone derivatives depends on the nature of the C18 substituent. , 1995, Endocrinology.

[28]  J. Gustafsson,et al.  Role of estrogen receptor beta in estrogen action. , 2001, Annual review of physiology.

[29]  B. Katzenellenbogen,et al.  Novel Ligands that Function as Selective Estrogens or Antiestrogens for Estrogen Receptor-α or Estrogen Receptor-β. , 1999, Endocrinology.